Veradermics, Inc (MANE) stock
MANENYSEPharmaceutical PreparationsFiscal year ends December 31
$129.66−5.63 (-4.16%)
Close on Nov 13, 2026Market cap $5.42BP/E –Yield –
Veradermics cash
Cash and short-term investments held at the end of each period.
Veradermics's cash was $798.40M at Sep 30, 2026. For fiscal 2025 it was $141.86M, up 167.2% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.86M | +167.2% |
| FY2024 | Dec 31, 2024 | $53.08M | +225.7% |
| FY2023 | Dec 31, 2023 | $16.30M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $798.40M | +14006.0% |
| Q2 FY2026 | Jun 30, 2026 | $819.90M | +9438.2% |
| Q1 FY2026 | Mar 31, 2026 | $390.80M | +1104.7% |
| Q4 FY2025 | Dec 31, 2025 | $141.86M | +167.2% |
| Q3 FY2025 | Sep 30, 2025 | $5.66M | -65.3% |
| Q2 FY2025 | Jun 30, 2025 | $8.60M | – |
| Q1 FY2025 | Mar 31, 2025 | $32.44M | – |
| Q4 FY2024 | Dec 31, 2024 | $53.08M | – |
| Q4 FY2023 | Dec 31, 2023 | $16.30M | – |
See a number that looks wrong?